Kymera IPO Presentation Deck

KT-474: Close to Complete IRAK4 Degradation and Well Tolerated in Preclinical Non-rodent Model • Orally-administered KT-474 evaluated in a 14-day non- GLP tox and PKPD study in rodent and non-rodents (shown). • Almost complete knockdown demonstrated across multiple tissues at multiple doses Compound well-tolerated at all doses up to 600 mg/kg for rodents and 100 mg/kg for non-rodents KYMERA % IRAK4 (Control) % IRAK4 (Control) 150- 50 150- 100 0 0 PBMC 10 30 Dose (mg/kg/day) Kidney Dose (mg/kg/day) % IRAK4 (Control) % IRAK4 (Control) 150- 150 100 10 Skin Dose (mg/kg/day) Liver # 100 Dose (mg/kg/day) % IRAK4 (Control) % IRAK4 (Control) 150- 50 10 150- 2 Spleen Dose (mg/kg/day) Lymph Node 0 10 Dose (mg/kg/day) Vehicle 10mg/kg/day 30 mg/kg/day 100 mg/kg/day *- Below level of quantification

View entire presentation